Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme
Grant Award Details
Grant Type:
Grant Number:
CLIN2-15094
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$11,999,991
Status:
Active
Grant Application Details
Application Title:
Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme
Public Abstract:
Therapeutic Candidate or Device
Autologous T cells genetically engineered to express a Chimeric Antigen Receptor targeting B7-H3 (B7-H3CART)
Indication
Brain tumors in adults: Glioblastoma Multiforme (GBM)
Therapeutic Mechanism
Progenitor B7-H3CART cells will recognize GBM cancer cells expressing B7-H3, become activated, divide, and kill the cancer cells
Unmet Medical Need
Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor in adults. The long-term prognosis for GBM remains grim, and current treatments show limited improvement in overall survival. Thus, there is an urgent need for novel effective therapies.
Project Objective
Phase 1 trial completed
Major Proposed Activities
Autologous T cells genetically engineered to express a Chimeric Antigen Receptor targeting B7-H3 (B7-H3CART)
Indication
Brain tumors in adults: Glioblastoma Multiforme (GBM)
Therapeutic Mechanism
Progenitor B7-H3CART cells will recognize GBM cancer cells expressing B7-H3, become activated, divide, and kill the cancer cells
Unmet Medical Need
Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor in adults. The long-term prognosis for GBM remains grim, and current treatments show limited improvement in overall survival. Thus, there is an urgent need for novel effective therapies.
Project Objective
Phase 1 trial completed
Major Proposed Activities
- Determine recommended Phase 2 dose of therapeutic for patients with GBM
- Assess toxicity of B7-H3CART cells
- Assess clinical activity of B7-H3CART cells in adults with GBM
Statement of Benefit to California:
Glioblastoma Multiforme (GBM) is the most common malignant primary brain tumor in adults. With standard of care therapies, the long-term prognosis for GBM is grim, with an estimated 5-year survival rate of 6.8% and a 10-year survival rate of <1%. We propose to conduct a Phase 1 clinical trial of novel B7-H3 targeting CAR T cells, which have shown impressive antitumor activity in preclinical studies. If successful, this therapy would transform the landscape for this lethal brain tumor.
